ClinicalTrials.gg
CompletedNCT04254939Updated Apr 27, 2023

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

A Phase 1/2 interventional study of CS3007 (BLU-285) in Gastrointestinal Stromal Tumors, sponsored by CStone Pharmaceuticals. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by CStone Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2019, registered Dec 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.

Enrollment
31st of 46
65 · median 100
Started
2019
with 2 others
Phase 1/2
Only one
of the 69
Registered
25th of 69
by date
Lead sponsor
2 of 69
CStone Pharmaceuticals

Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 31st largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2019, is the only one in phase 1/2, and was the 25th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gastrointestinal Stromal Tumors with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST. The study consists of two parts: dose escalation (phase I) and dose expansion (phase II).

03

Conditions studied

  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For phase I study, the subject must have or cytologically confirmed unresectable or GIST that progressed after imatinib and at least one additional TKI treatment, or who cannot tolerate the standard treatment or have D842V mutation in the PDGFRα gene.
  2. For phase II study:

    i) Group 1: Chinese subjects with unresectable GIST harboring D842V mutation in PDGFRα gene.

    ii) Group 2: Chinese and fourth-line or later subjects with unresectable GIST that has progressed after standard treatment and/or do not tolerate standard treatment, and do not have a known D842V mutation in the PDGFRα gene.

  3. Subjects with at least one as defined per v1.1
  4. (ECOG) performance status of 0 to 1.

Exclusion criteria

Exclusion Criteria

  1. Subject has any of the laboratory results that meet exclusion criteria
  2. Subjects who have previously received antineoplastic medication, including Chinese herbal drugs or Chinese medicine products with antineoplastic indications, for less than 5 half-lives or 14 days, whichever is shorter, prior to the first dose of the product.
  3. The subject received neutrophil growth factor support within 14 days prior to the first dose of investigational product.
  4. Subjects received treatment with a strong inhibitor or strong or moderate inducer of cytochrome P450 (CYP) 3A4 within 14 days prior to the first dose of study drug, or requires continuous intake of above medications or foods during study period.
  5. Subject received a major surgery (not including minor procedures, e.g., central venous catheterization, tumor needle , feeding tube placement) within 14 days prior to the first dose of investigational product.
  6. Diagnosis of any other within 1 year prior to the first dose of investigational product or the subject is under treatment for another malignancy.
  7. interval > 450 msec calculated using Fridericia's formula.
  8. Subject has history of seizure (e.g. epilepsy) or requires antiepileptic medication treatment.
  9. History of cerebrovascular accident or within one year prior to the first dose of the investigational product.
  10. Known risk of intracranial hemorrhage, e.g., history of cerebral aneurysm or subdural or subarachnoid hemorrhage.
  11. With primary brain malignancy or .
  12. With , uncontrolled cardiovascular disease, including congestive heart failure of (NYHA) class II, III or IV, myocardial infarction or unstable angina in the past 6 months, or uncontrolled hypertension.
  13. Unwilling or unable to comply with scheduled visits, treatment plan, laboratory tests or other study procedures/restrictions.
  14. With previous or current clinically significant disorder, medical condition, history of surgery, physical issue or laboratory finding, which, in the investigator's judgment, might affect the subject's safety, change the absorption, distribution, metabolism or excretion of the investigational product, or interfere with the evaluation of study result.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    CS3007(BLU-285)

    Drug: CS3007 (BLU-285)

Interventions

  • A modified "3+3" dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.

06

What researchers measure

Primary outcomes

  1. Phase I: Recommended Phase II dose (RP2D), incidence of dose limiting toxicities (DLT) in Cycle 1, incidence and severity of adverse events and serious adverse events and changes in vital signs, clinical laboratory results and ECG findings

    Time frame: at the end of Cycle 1 (each cycle is 28 days) for RP2D and DLT; during every cycle through 30 days after the last dose of study drug, an average of approximately 24 months, for other measures

  2. Phase II: ORR based on mRESIST 1.1

    Time frame: At Cycle 3 (each cycle is 28 days) Day 1, then every 2 cycles until Cycle 13, they every 3 cycles through study completion, disease progression or patient discontinuation from the study (whichever comes first), an average of approximately 24 months

07

Study locations

16 sites
  • Beijing Cancer Hospital
    Beijing, Beijing, China
  • Chinese PLA General Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • The Sixth Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • The First Affiliated Hospital of Nanchang Medical University
    Nanchang, Jiangxi, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai, China
  • Fudan University Zhongshan Hospital (General Surgery Department)
    Shanghai, Shanghai, China
  • Fudan University Zhongshan Hospital (Internal Tumor Department)
    Shanghai, Shanghai, China
  • Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Xinjiang Medical University Cancer Hospital
    Urumqi, Xinjiang, China
  • The First Affiliated Hospital Zhe Jiang University
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Apr 2020, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Feb 5, 2020
StartActual
Aug 15, 2019
Primary completionActual
Apr 30, 2020
CompletionActual
Apr 11, 2023
Last update
Apr 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04254939
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Aug 15, 2019
Primary completion
Apr 30, 2020
Completion
Apr 11, 2023
Last update
Apr 27, 2023

Study contacts

Lin SHEN, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion